• 1. Emerging 2D hybrid nanomaterials: towards enhanced sensitive and selective conductometric gas sensors at room temperature
  Hanie Hashtroudi,Ian D. R. Mackinnon J. Mater. Chem. C, 2020,8, 13108-13126
• 2. Establishment and implications of a characterization method for magnetic nanoparticle using cell tracking velocimetry and magnetic susceptibility modified solutions
  Huading Zhang,Lee R. Moore,Maciej Zborowski,P. Stephen Williams,Shlomo Margel,Jeffrey J. Chalmers Analyst, 2005,130, 514-527
• 3. Emergence of cationic polyamine dendrimersomes: design, stimuli sensitivity and potential biomedical applications
  Partha Laskar,Christine Dufès Nanoscale Adv., 2021,3, 6007-6026
• 4. Excitable dynamics in the bromate–sulfite–ferrocyanide reaction
  J. Zagora,M. Vosla?,L. Schreiberová,I. Schreiber Phys. Chem. Chem. Phys., 2002,4, 1284-1291
• 5. Establishing empirical design rules of nucleic acid templates for the synthesis of silver nanoclusters with tunable photoluminescence and functionalities towards targeted bioimaging applications?
  Jason Y. C. Lim,Yong Yu,Guorui Jin,Kai Li,Yi Lu,Jianping Xie Nanoscale Adv., 2020,2, 3921-3932

• Solvents and Organic Chemicals Organic Compounds Organoheterocyclic compounds Azoles Triazoles Triazolones

Introduction to 7-(trifluoromethyl)-1,2,4triazolo[4,3-α]pyridin-3-ol (CAS No. 1613150-00-7)

7-(trifluoromethyl)-1,2,4triazolo[4,3-α]pyridin-3-ol, identified by its Chemical Abstracts Service (CAS) number 1613150-00-7, is a heterocyclic compound that has garnered significant attention in the field of pharmaceutical chemistry and medicinal biology. This compound belongs to the triazolo-pyridine class of scaffolds, which are known for their structural versatility and biological activity. The presence of a trifluoromethyl group at the 7-position and the unique arrangement of the triazole and pyridine rings contribute to its distinctive chemical properties and potential applications in drug discovery.

The trifluoromethyl group is a key structural feature that enhances the metabolic stability and lipophilicity of the molecule. This modification is widely employed in medicinal chemistry to improve pharmacokinetic profiles, particularly in terms of bioavailability and resistance to metabolic degradation. The incorporation of this group into 7-(trifluoromethyl)-1,2,4triazolo[4,3-α]pyridin-3-ol suggests that it may exhibit improved pharmacological properties compared to its unsubstituted counterparts.

The triazolo-pyridine core is a privileged scaffold in drug design due to its ability to interact with various biological targets. Specifically, this motif has been extensively studied for its potential as an antiviral, anticancer, and anti-inflammatory agent. The 1,2,4-triazole ring provides a rigid structure that can facilitate binding to biological macromolecules, while the pyridine moiety allows for further functionalization and interaction with enzymes or receptors. The specific arrangement of these rings in 7-(trifluoromethyl)-1,2,4triazolo[4,3-α]pyridin-3-ol may confer unique binding affinities and selectivity.

Recent advancements in computational chemistry and molecular modeling have enabled researchers to predict the biological activity of heterocyclic compounds with greater accuracy. Studies have shown that the trifluoromethyl group can modulate electronic properties and influence binding interactions at the molecular level. In the context of 7-(trifluoromethyl)-1,2,4triazolo[4,3-α]pyridin-3-ol, this group may enhance binding affinity to target proteins by increasing hydrophobic interactions or by stabilizing specific conformational states.

The pyridin-3-ol moiety in this compound introduces a hydroxyl group that can participate in hydrogen bonding interactions. This feature is particularly relevant for designing molecules that interact with biological targets such as kinases or transcription factors. Hydrogen bonding networks play a crucial role in determining binding affinity and specificity, making the hydroxyl group a valuable tool for medicinal chemists.

In recent years, there has been growing interest in developing novel therapeutic agents based on triazolo-pyridine scaffolds. Several patents and scientific publications have highlighted the potential of these compounds as lead candidates for treating various diseases. For instance, derivatives of triazolo-pyridines have been investigated for their antiviral properties against RNA viruses, including SARS-CoV-2. The structural features of 7-(trifluoromethyl)-1,2,4triazolo[4,3-α]pyridin-3-ol, particularly the trifluoromethyl group and the rigid heterocyclic core, make it a promising candidate for further exploration in this area.

Moreover, the compound's potential as an anticancer agent has not been overlooked. Triazolo-pyridines have been shown to inhibit various kinases involved in cancer cell proliferation and survival. The unique combination of structural elements in 7-(trifluoromethyl)-1,2,4triazolo[4,3-α]pyridin-3-ol may enable it to disrupt critical signaling pathways associated with cancer development. Preclinical studies are needed to validate these hypotheses and determine whether this compound exhibits sufficient efficacy and safety profiles for therapeutic use.

The synthesis of 7-(trifluoromethyl)-1,2,4triazolo[4,3-α]pyridin-3-ol presents an interesting challenge due to the complexity of its heterocyclic framework. However, modern synthetic methodologies have made significant progress in facilitating the construction of such molecules. Techniques such as transition-metal-catalyzed cross-coupling reactions and palladium-mediated cyclizations have been instrumental in building triazolo-pyridine derivatives efficiently. These advances have enabled researchers to explore a wide range of structural variations and optimize synthetic routes for large-scale production.

The pharmacokinetic properties of 7-(trifluoromethyl)-1,2,4triazolo[4,3-α]pyridin-3-ol are also worthy of consideration. The presence of the trifluoromethyl group can influence metabolic pathways by affecting electron distribution and reactivity at key positions within the molecule. Additionally，the hydroxyl group may impact solubility and absorption rates following oral administration. Understanding these properties is essential for predicting how well the compound will perform in vivo and for designing appropriate dosing regimens.

In conclusion,7-(trifluoromethyl)-1，2，4-triazolo[4，3-a]pyridin - 3 - ol (CAS No．1613150 - 00 - 7) is a structurally intriguing heterocyclic compound with potential applications across multiple therapeutic areas．The combination of its unique scaffold，the presence of a key pharmacophore，and recent advances in synthetic chemistry make it an attractive candidate for further investigation．Future studies should focus on elucidating its biological activity，optimizing its pharmacokinetic profile，and exploring its potential as a lead compound for drug development．

• 2098070-20-1(2-(3-(Pyridin-3-yl)-1H-pyrazol-1-yl)acetimidamide)
• 2680771-01-9(4-cyclopentyl-3-{(prop-2-en-1-yloxy)carbonylamino}butanoic acid)
• 1444113-98-7(N-(3-cyanothiolan-3-yl)-2-[(2,2,2-trifluoroethyl)sulfanyl]pyridine-4-carboxamide)
• 332062-08-5(Fmoc-S-3-amino-4,4-diphenyl-butyric acid)
• 1270529-38-8(1,2,3,4,5,6-Hexahydro-[2,3]bipyridinyl-6-ol)
• 941977-17-9(N'-(3-chloro-2-methylphenyl)-N-2-(dimethylamino)-2-(naphthalen-1-yl)ethylethanediamide)
• 2138166-62-6(2,2-Difluoro-3-[methyl(2-methylbutyl)amino]propanoic acid)
• 89640-58-4(2-Iodo-4-nitrophenylhydrazine)
• 1449132-38-0(3-Fluoro-5-(2-fluoro-5-methylbenzylcarbamoyl)benzeneboronic acid)
• 2034271-14-0(2-(1H-indol-3-yl)-N-{[6-(thiophen-2-yl)-[1,2,4]triazolo[4,3-b]pyridazin-3-yl]methyl}acetamide)